Amylyx Pharmaceuticals Inc. Common Stock (AMLX)

FairStock Score: 39/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Graham-style investor, I look first for durable earnings and a margin of safety. Amylyx does not fit that mold today. It is a clinical-stage drug developer with 136 employees, and its filings show a business that once sold product but now subsists on pipeline hope. In fiscal 2023 (ended 2023-12-31), it reported revenue of $380.8M, net income of $49.3M and EPS of $0.70. By fiscal 2024 (ended 2024-12-31), revenue fell to $87.4M, and it lost $301.7M, or $4.43 per diluted share. Fiscal 2025 (ended 2025-12-31) showed no revenue in the filed figures and a net loss of $144.7M, or $1.53 per share. More recently, fiscal Q1 2026 (ended 2026-03-31) lost $41.3M, or $0.37 per share, and fiscal Q2 2026 (ended 2026-06-30) lost $43.4M, or $0.39 per share. That is not a turnaround yet; it is continuing cash consumption. The balance sheet gives some comfort: D/E is only 0.02 and the Altman Z-Score is 66.81. But trailing free cash flow is -$126.7M, ROE is -74.73%, ROCE is -44.13%, and the Piotroski F-Score is 1/9. At the 2026-10-13 close of $26.85, FairStock's P/B is 12.49, P/E is -19.04, and FCF yield is -4.2%. The $3.0B market cap and FairStock score of 39/100 price in a lot of clinical success for Avexitide or AMX0035. I see no durable moat and no Graham-style bargain.

In plain English: Amylyx is a small drug company testing treatments for brain and hormone-related diseases. It is losing money, has no recent revenue shown in its latest filed figures, and burns cash. At $26.85, the price looks expensive compared with its accounting value and lack of profits.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer